Cerebral cavernous malformation is a cerebrovascular malformation disorder characterized by low-flow clusters of dilated, thin-walled sinusoidal vascular channels in the central nervous system. Lesions may be sporadic or familial and can present with seizures, focal neurological deficits, intracranial hemorrhage, or clinically silent MRI findings.
Ask a research question about Cerebral Cavernous Malformation. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Cerebral Cavernous Malformation
creation_date: "2026-05-04T22:23:50Z"
updated_date: "2026-05-04T22:23:50Z"
description: >-
Cerebral cavernous malformation is a cerebrovascular malformation disorder
characterized by low-flow clusters of dilated, thin-walled sinusoidal vascular
channels in the central nervous system. Lesions may be sporadic or familial
and can present with seizures, focal neurological deficits, intracranial
hemorrhage, or clinically silent MRI findings.
category: Mendelian
disease_term:
preferred_term: cerebral cavernous malformation
term:
id: MONDO:0000820
label: cerebral cavernous malformation
parents:
- Vascular disorder
synonyms:
- CCM
- Cavernoma
- Cavernous angioma
- Cavernous malformation
- Cavernous hemangioma
has_subtypes:
- name: Familial cerebral cavernous malformation
display_name: Familial cerebral cavernous malformation
subtype_term:
preferred_term: familial cerebral cavernous malformations
term:
id: MONDO:0031037
label: famililal cerebral cavernous malformations
genes:
- preferred_term: KRIT1
term:
id: hgnc:1573
label: KRIT1
- preferred_term: CCM2
term:
id: hgnc:21708
label: CCM2
- preferred_term: PDCD10
term:
id: hgnc:8761
label: PDCD10
description: >-
Autosomal dominant familial CCM is the inherited, gene-heterogeneous form
caused by loss-of-function in one of the CCM-complex genes.
evidence:
- reference: PMID:33234067
reference_title: Signalling through cerebral cavernous malformation protein networks.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
CCMs arise due to loss-of-function mutations in genes encoding one of three CCM complex proteins, KRIT1, CCM2 or CCM3.
explanation: This review defines familial CCM by loss-of-function in the three CCM-complex genes.
- name: CCM1
display_name: CCM1 (KRIT1-related cerebral cavernous malformation)
subtype_term:
preferred_term: cerebral cavernous malformation 1
term:
id: MONDO:0020724
label: cerebral cavernous malformation 1
genes:
- preferred_term: KRIT1
term:
id: hgnc:1573
label: KRIT1
description: >-
KRIT1-related familial CCM, historically designated CCM1.
evidence:
- reference: PMID:10545614
reference_title: "Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Using a genomic sequence-based positional cloning strategy, we have identified KRIT1, encoding a protein that interacts with the Krev-1/rap1a tumor suppressor, as the CCM1 gene.
explanation: This positional-cloning study identifies KRIT1 as the CCM1 gene.
- name: CCM2
display_name: CCM2-related cerebral cavernous malformation
subtype_term:
preferred_term: cerebral cavernous malformation 2
term:
id: MONDO:0011304
label: cerebral cavernous malformation 2
genes:
- preferred_term: CCM2
term:
id: hgnc:21708
label: CCM2
description: >-
CCM2-related familial CCM. Pediatric familial CCM cohorts suggest this
genotype may carry higher 5-year symptomatic hemorrhage risk.
evidence:
- reference: PMID:14624391
reference_title: Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We report that a novel gene, MGC4607, exhibits eight different mutations in nine families with type 2 CCM (CCM2).
explanation: This study identifies MGC4607/CCM2 mutations in families with type 2 CCM.
- reference: DOI:10.1007/s00234-022-03056-y
reference_title: "Natural history of familial cerebral cavernous malformation syndrome in children: a multicenter cohort study"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The latter was higher in children with prior symptomatic hemorrhage (33.3%), CCM2 genotype (33.3%), and positive family history (20.7%).
explanation: This pediatric familial CCM cohort supports the reviewer-noted CCM2 genotype hemorrhage-risk signal.
- name: CCM3
display_name: CCM3 (PDCD10-related cerebral cavernous malformation)
subtype_term:
preferred_term: cerebral cavernous malformation 3
term:
id: MONDO:0011305
label: cerebral cavernous malformation 3
genes:
- preferred_term: PDCD10
term:
id: hgnc:8761
label: PDCD10
description: >-
PDCD10-related familial CCM, historically designated CCM3.
evidence:
- reference: PMID:15543491
reference_title: Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We report herein the identification of PDCD10 (programmed cell death 10) as the CCM3 gene.
explanation: This study identifies PDCD10 as the CCM3 gene.
pathophysiology:
- name: Endothelial low-flow cavernoma formation
description: >-
CCM lesions are low-flow vascular structures formed by sinusoidal spaces
lined by endothelium and separated by abnormal collagenous matrix lacking
normal smooth muscle, elastin, and vessel-wall support; this fragile
architecture predisposes to leakage and hemorrhage.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: vasculature development
modifier: ABNORMAL
term:
id: GO:0001944
label: vasculature development
- preferred_term: extracellular matrix organization
modifier: ABNORMAL
term:
id: GO:0030198
label: extracellular matrix organization
evidence:
- reference: DOI:10.1055/s-0044-1779587
reference_title: "Giant Intracranial Cavernous Malformations: A Review on Magnetic Resonance Imaging Characteristics"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Intracranial cavernous malformations (CMs), commonly known as cavernomas or cavernous angiomas, are low-flow, well-circumscribed vascular lesions composed of sinusoidal spaces lined by a single layer of endothelium and separated by a collagenous matrix without elastin, smooth muscle, or other vascular wall elements.
explanation: This directly describes CCM lesion architecture and endothelial composition.
- name: Familial CCM gene loss and endothelial signaling dysregulation
description: >-
Familial CCM is driven by loss-of-function in KRIT1, CCM2, or PDCD10, often
modeled as a germline first hit followed by lesion-level somatic loss. Loss
of CCM-complex function perturbs endothelial barrier stability,
cytoskeletal organization, and angiogenic remodeling.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: angiogenesis
modifier: ABNORMAL
term:
id: GO:0001525
label: angiogenesis
- preferred_term: actin cytoskeleton organization
modifier: ABNORMAL
term:
id: GO:0030036
label: actin cytoskeleton organization
evidence:
- reference: PMID:15543491
reference_title: Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Three CCM loci have been mapped, and loss-of-function mutations were identified in the KRIT1 (CCM1) and MGC4607 (CCM2) genes.
explanation: This abstract supports familial CCM as a genetically mapped disorder involving loss-of-function CCM genes.
- name: MEKK3-MEK5-ERK5-KLF2/4 endothelial signaling activation
description: >-
Loss of CCM-complex restraint activates the endothelial MEKK3-MEK5-ERK5
cascade and increases KLF2/KLF4 transcriptional programs, a central
signaling mechanism for CCM lesion biology.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: ERK5 cascade
modifier: INCREASED
term:
id: GO:0070375
label: ERK5 cascade
evidence:
- reference: PMID:33234067
reference_title: Signalling through cerebral cavernous malformation protein networks.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Here, we review current knowledge of CCM protein signalling with a focus on three pathways which have generated the most interest-the RhoA-ROCK, MEKK3-MEK5-ERK5-KLF2/4 and cell junctional signalling pathways-but also consider ICAP1-β1 integrin and cdc42 signalling.
explanation: This review identifies the MEKK3-MEK5-ERK5-KLF2/4 pathway as one of the core CCM signaling mechanisms.
- reference: PMID:30732528
reference_title: CDC42 Deletion Elicits Cerebral Vascular Malformations via Increased MEKK3-Dependent KLF4 Expression.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Mechanistically, CDC42 depletion in ECs elicited increased MEKK3 (mitogen-activated protein kinase kinase kinase 3)-MEK5 (mitogen-activated protein kinase kinase 5)-ERK5 (extracellular signal-regulated kinase 5) signaling and consequent detrimental overexpression of KLF (Kruppel-like factor) 2 and KLF4, recapitulating the hallmark mechanism for CCM pathogenesis.
explanation: This mouse endothelial study provides mechanistic support for MEKK3-MEK5-ERK5-KLF2/4 activation as a CCM-like malformation driver.
- name: RhoA/ROCK cytoskeletal overactivation
description: >-
CCM-complex loss can increase RhoA/ROCK activity, producing endothelial
stress-fiber remodeling and junctional instability that contribute to leaky
cavernous vascular lesions.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: actin cytoskeleton organization
modifier: INCREASED
term:
id: GO:0030036
label: actin cytoskeleton organization
evidence:
- reference: PMID:33234067
reference_title: Signalling through cerebral cavernous malformation protein networks.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
These widely expressed, multi-functional adaptor proteins can assemble into a CCM protein complex and (either alone or in complex) modulate signalling pathways that influence cell adhesion, cell contractility, cytoskeletal reorganization and gene expression.
explanation: This review links CCM-complex proteins to contractility and cytoskeletal pathways relevant to RhoA/ROCK signaling.
- reference: DOI:10.3390/kinasesphosphatases1010006
reference_title: Therapeutic Perspectives on ROCK Inhibition for Cerebral Cavernous Malformations
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The study of lesion biology led to the identification of different pathways related to disease onset and progression, of which RhoA/Rho-associated protein kinase (ROCK) shows activation in different subsets of patients.
explanation: This review directly supports RhoA/ROCK activation as a CCM disease mechanism and therapeutic target.
phenotypes:
- category: Neurological
name: Intracranial hemorrhage
description: CCM lesions can cause symptomatic intracranial hemorrhage, with risk varying by presentation, lesion location, and familial status.
phenotype_term:
preferred_term: Intracranial hemorrhage
term:
id: HP:0002170
label: Intracranial hemorrhage
evidence:
- reference: DOI:10.1007/s10143-023-01949-x
reference_title: "Predictors of future haemorrhage from cerebral cavernous malformations: a retrospective cohort study"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The annual haemorrhage rate was 1.00% per lesion-year (25 events in 2512 lesion-years), and higher in those with symptoms at presentation (1.50% per lesion-year, 22 events vs 0.29%, 3 events, P < 0.001).
explanation: This cohort quantifies symptomatic hemorrhage risk in CCM.
- category: Neurological
name: Seizure
description: Seizures are a common presentation or follow-up event in familial CCM.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
evidence:
- reference: DOI:10.3171/2023.1.JNS222434
reference_title: "Clinical presentation, hemorrhage risk, and outcome in patients with familial cavernous malformations: a pragmatic prospective analysis of 75 patients"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Over an average of 9.9 years, the rate of prospective hemorrhage was 4.0% per patient-year, and the rate of new seizure was 1.2% per patient-year, with 64% and 32% of patients experiencing at least one symptomatic hemorrhage and at least one seizure, respectively.
explanation: This prospective familial CCM cohort supports seizure and hemorrhage burden.
- category: Neurological
name: Multiple lesions in familial CCM
diagnostic: true
frequency: OCCASIONAL
description: Familial CCM commonly involves multiple brain lesions detectable on MRI.
phenotype_term:
preferred_term: Multiple cerebral cavernous malformations
term:
id: HP:0001048
label: Cavernous hemangioma
evidence:
- reference: DOI:10.1007/s10143-023-01949-x
reference_title: "Predictors of future haemorrhage from cerebral cavernous malformations: a retrospective cohort study"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Of the patients, 15.0% had multiple lesions (N = 82/545).
explanation: This cohort supports multiple lesions as a recognized CCM imaging pattern, although it includes sporadic and familial cases.
- category: Neurological
name: Stroke and focal neurological deficits
description: Stroke and focal neurological deficits are recognized CCM manifestations, often occurring in the context of hemorrhage or lesion location.
phenotype_term:
preferred_term: Stroke
term:
id: HP:0001297
label: Stroke
evidence:
- reference: PMID:33234067
reference_title: Signalling through cerebral cavernous malformation protein networks.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Cerebral cavernous malformations (CCMs) are neurovascular abnormalities characterized by thin, leaky blood vessels resulting in lesions that predispose to haemorrhages, stroke, epilepsy and focal neurological deficits.
explanation: This review explicitly identifies focal neurological deficits as a CCM manifestation.
genetic:
- name: KRIT1 familial CCM
gene_term:
preferred_term: KRIT1
term:
id: hgnc:1573
label: KRIT1
association: Causative
presence: Positive
inheritance:
- name: Autosomal dominant inheritance
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
notes: >-
KRIT1 loss-of-function causes autosomal dominant CCM1 with incomplete penetrance.
evidence:
- reference: PMID:10545614
reference_title: "Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Using a genomic sequence-based positional cloning strategy, we have identified KRIT1, encoding a protein that interacts with the Krev-1/rap1a tumor suppressor, as the CCM1 gene.
explanation: This positional-cloning study identifies KRIT1 as the CCM1 gene.
- name: CCM2 familial CCM
gene_term:
preferred_term: CCM2
term:
id: hgnc:21708
label: CCM2
association: Causative
presence: Positive
inheritance:
- name: Autosomal dominant inheritance
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
notes: >-
CCM2 loss-of-function causes autosomal dominant CCM2 with incomplete penetrance.
evidence:
- reference: PMID:14624391
reference_title: Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We report that a novel gene, MGC4607, exhibits eight different mutations in nine families with type 2 CCM (CCM2).
explanation: This study identifies MGC4607/CCM2 mutations in families with type 2 CCM.
- name: PDCD10 familial CCM
gene_term:
preferred_term: PDCD10
term:
id: hgnc:8761
label: PDCD10
association: Causative
presence: Positive
inheritance:
- name: Autosomal dominant inheritance
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
notes: >-
PDCD10 loss-of-function causes autosomal dominant CCM3 with incomplete penetrance.
evidence:
- reference: PMID:15543491
reference_title: Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We report herein the identification of PDCD10 (programmed cell death 10) as the CCM3 gene.
explanation: This study identifies PDCD10 as the CCM3 gene.
diagnosis:
- name: Brain MRI with susceptibility-sensitive sequences
description: >-
MRI is the key diagnostic modality; susceptibility-weighted or T2-gradient
echo sequences improve detection of hemosiderin and small lesions.
diagnosis_term:
preferred_term: diagnostic imaging
results: MRI may show popcorn-like cavernomas, hemosiderin rims, blooming, multifocal lesions, edema, or repeated hemorrhage features.
evidence:
- reference: DOI:10.1055/s-0044-1779587
reference_title: "Giant Intracranial Cavernous Malformations: A Review on Magnetic Resonance Imaging Characteristics"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MRI with advanced techniques such as a susceptibility-weighted image or T2-gradient echo, a diffusion-weighted image and corresponding apparent diffusion coefficient map, and diffusion tensor tractography have revolutionized the diagnostic approach to these lesions.
explanation: This supports MRI and susceptibility-sensitive approaches for diagnosis.
treatments:
- name: Neurosurgical treatment of selected symptomatic lesions
description: >-
Surgery is used selectively for symptomatic, surgically accessible, or
recurrently hemorrhagic lesions; management balances hemorrhage and seizure
risk against operative morbidity.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: DOI:10.3171/2023.1.JNS222434
reference_title: "Clinical presentation, hemorrhage risk, and outcome in patients with familial cavernous malformations: a pragmatic prospective analysis of 75 patients"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Thirty-eight percent of the patients underwent at least 1 surgery and 5.3% underwent stereotactic radiosurgery.
explanation: This prospective familial cohort documents surgical and radiosurgical treatment use.
- name: Investigational atorvastatin pharmacotherapy
description: >-
Atorvastatin is being tested as investigational medical therapy for
symptomatic CCM, with a rationale of indirect ROCK-pathway modulation and
MRI biomarker readouts rather than established routine disease-modifying use.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: atorvastatin
term:
id: CHEBI:39548
label: atorvastatin
target_mechanisms:
- target: RhoA/ROCK cytoskeletal overactivation
treatment_effect: INHIBITS
description: Atorvastatin is an investigational indirect ROCK-modulating treatment strategy in CCM.
evidence:
- reference: clinicaltrials:NCT02603328
reference_title: "Phase I-II Randomized, Placebo-Controlled, Single-Blinded, Single-Site Clinical Trial of Atorvastatin in the Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by validated quantitative susceptibility mapping (QSM) MRI studies in patients who suffered a symptomatic bleed within the preceding one year.
explanation: This trial record directly supports atorvastatin as an investigational CCM pharmacotherapy.
evidence:
- reference: clinicaltrials:NCT02603328
reference_title: "Phase I-II Randomized, Placebo-Controlled, Single-Blinded, Single-Site Clinical Trial of Atorvastatin in the Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by validated quantitative susceptibility mapping (QSM) MRI studies in patients who suffered a symptomatic bleed within the preceding one year.
explanation: This clinical trial record supports adding atorvastatin as investigational pharmacotherapy for symptomatic CCM.
clinical_trials:
- name: NCT02603328
phase: PHASE_II
status: COMPLETED
description: >-
AT CASH EPOC tested prolonged atorvastatin versus placebo in patients with
CCM and symptomatic hemorrhage, using quantitative susceptibility mapping
MRI of lesional iron deposition as the biomarker endpoint.
evidence:
- reference: clinicaltrials:NCT02603328
reference_title: "Phase I-II Randomized, Placebo-Controlled, Single-Blinded, Single-Site Clinical Trial of Atorvastatin in the Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC)"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by validated quantitative susceptibility mapping (QSM) MRI studies in patients who suffered a symptomatic bleed within the preceding one year.
explanation: This identifies the atorvastatin AT CASH EPOC CCM trial and its MRI biomarker endpoint.
- name: NCT03589014
phase: PHASE_II
status: COMPLETED
description: >-
Treat_CCM was a randomized propranolol trial in familial CCM intended to
reduce lesion burden, clinical events, and symptoms.
evidence:
- reference: clinicaltrials:NCT03589014
reference_title: Treat_CCM Clinical Trial A Multicenter Randomized Clinical Trial on Propranolol in Familial Cerebral Cavernous Malformation
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The primary objective of this exploratory trial is to test whether a chronic treatment with propranolol will reduce the burden of cerebrovascular lesions, of clinical events and symptoms in patients with familial CCM.
explanation: This trial record supports propranolol as an interventional familial CCM trial.
- name: NCT05085561
phase: PHASE_II
status: COMPLETED
description: >-
This trial evaluated REC-994 doses versus placebo in adults with symptomatic
CCM, with a long-term blinded extension for safety, tolerability, and efficacy.
evidence:
- reference: clinicaltrials:NCT05085561
reference_title: "A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic cerebral cavernous malformation (CCM).
explanation: This clinical trial record supports REC-994 as a completed Phase 2 symptomatic CCM trial.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Cerebral Cavernous Malformation covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Cerebral cavernous malformation (CCM) is a cerebrovascular disorder characterized by clusters of thin-walled, dilated capillary/capillary–venous channels lined by a single endothelial layer with deficient mural support and barrier dysfunction, predisposing to microbleeds and intracranial hemorrhage. (min2023endothelialcellpericyteinteractions pages 1-2, montagnoli2023therapeuticperspectiveson pages 2-4, montagnoli2023therapeuticperspectiveson pages 1-2) The Mendelian (familial) form is typically autosomal dominant with incomplete penetrance and is caused by loss-of-function variants in KRIT1 (CCM1), CCM2, or PDCD10 (CCM3), consistent with a two-hit lesion model in which somatic biallelic loss occurs in lesion-forming endothelial cells. (min2023endothelialcellpericyteinteractions pages 1-2, shapeti2024forcemediatedangiogenesislinking pages 39-43) Recent 2023–2024 literature emphasizes convergent endothelial signaling nodes—MEKK3–MEK5–ERK5–KLF2/4, RhoA/ROCK, EndMT, oxidative stress/redox and autophagy defects, ECM (hyaluronic acid/versican)–dependent modulation, and gut microbiome–linked inflammatory signaling—while clinical translational efforts increasingly rely on susceptibility-based MRI biomarkers (e.g., SWI/QSM) and pilot clinical trials of repurposed or novel agents. (abdelilahseyfried2024arenaissanceof pages 1-3, ayata2024roleofrhoassociated pages 1-2, perrelli2023krit1atraffic pages 15-16, yordanov2024hyaluronicacidturnover pages 1-3, srinath2023plasmametaboliteswith pages 2-3, NCT02603328 chunk 1)
CCMs are vascular lesions described as “clusters of enlarged, dilated capillary channels formed by a single layer of endothelium,” lacking key supporting elements (smooth muscle/pericytes, intact basal lamina), leading to thin, leaky vessels. (min2023endothelialcellpericyteinteractions pages 1-2, montagnoli2023therapeuticperspectiveson pages 2-4) A 2023 review describes CCMs as “developmental venous dysplasias” and emphasizes that lesions are angiographically occult and typically detected by MRI. (montagnoli2023therapeuticperspectiveson pages 1-2)
Not retrieved in current tool context: OMIM / Orphanet / ICD-10 / ICD-11 / MeSH identifiers were not directly accessible via the tool outputs used here; MONDO IDs above are provided as stable ontology identifiers for knowledge base linkage.
Common synonyms include cavernous malformation, cavernoma, cavernous angioma, and cavernous hemangioma. (shapeti2024forcemediatedangiogenesislinking pages 39-43, montagnoli2023therapeuticperspectiveson pages 1-2) “CASH” (cavernous angioma with symptomatic hemorrhage) is commonly used to denote a clinically aggressive/symptomatic hemorrhage subgroup, especially in biomarker studies. (srinath2023plasmametaboliteswith pages 1-2)
Information in this report comes from: - Aggregated disease-level resources and reviews (mechanisms, diagnostic standards). (min2023endothelialcellpericyteinteractions pages 1-2, abdelilahseyfried2024arenaissanceof pages 1-3, perrelli2023krit1atraffic pages 1-3) - Human cohorts (natural history, risk factors, medication associations). (gillespie2023predictorsoffuture pages 1-2, santos2023naturalcourseof pages 3-4, alalfi2023clinicalpresentationhemorrhage pages 2-3, zuurbier2023femalehormonetherapy pages 3-5) - Model organism / in vitro / engineered human vessel models (mechanistic dissection; preclinical interventions). (min2023endothelialcellpericyteinteractions pages 1-2, grdseloff2023impairedretinoicacid pages 4-5, grdseloff2023impairedretinoicacid pages 6-7, yordanov2024hyaluronicacidturnover pages 1-3) - ClinicalTrials.gov records (ongoing/completed interventional studies). (NCT05085561 chunk 1, NCT02603328 chunk 1, NCT03589014 chunk 2)
Inherited CCM is attributed to loss-of-function mutations in CCM1/KRIT1, CCM2, and CCM3/PDCD10 (autosomal dominant), with endothelial cell–intrinsic biology central to lesion formation. (min2023endothelialcellpericyteinteractions pages 1-2, abdelilahseyfried2024arenaissanceof pages 1-3)
A “two-hit” mechanism is supported for familial CCM: germline heterozygous loss plus somatic biallelic loss in lesion-forming endothelial cells/clones. (shapeti2024forcemediatedangiogenesislinking pages 39-43, min2023endothelialcellpericyteinteractions pages 1-2) More recent models highlight additional somatic drivers: co-occurring PIK3CA gain-of-function with CCM loss-of-function alleles and MAP3K3/MEKK3 alterations are discussed as accelerating lesion growth (“third-hit/cooperating driver” concept). (abdelilahseyfried2024arenaissanceof pages 1-3, shapeti2024forcemediatedangiogenesislinking pages 39-43)
Definitive protective environmental factors were not established in the extracted texts. Some observational studies hypothesize protective medication associations (e.g., antithrombotics/beta-blockers in some cohorts), but evidence is inconsistent and not sufficient here to assert protective effects as generalizable. (montagnoli2023therapeuticperspectiveson pages 2-4)
Gut microbiome–linked inflammatory signaling has been proposed to interface with endothelial signaling in cavernous angioma/CCM, including “TLR4-MEKK3-KLF2/4 signaling, driven by the gut microbiome via gram-negative bacterial lipopolysaccharide.” (srinath2023plasmametaboliteswith pages 11-13)
Below, “HPO suggestions” are ontology recommendations; exact HPO IDs should be verified against the HPO browser.
1) Intracranial hemorrhage / symptomatic hemorrhage (clinical sign/outcome) - HPO suggestions: Intracranial hemorrhage; Cerebral hemorrhage. - Frequency/risk examples: - Overall annual symptomatic hemorrhage rate 1.00% per lesion-year in a 545-patient cohort; higher when symptomatic at presentation (1.50% vs 0.29%). (gillespie2023predictorsoffuture pages 1-2) - Conservatively managed 10-year cohort: overall 10-year cumulative risk 30%; brainstem 10-year risk 33%; spinal 10-year risk 67%; asymptomatic 0%. (santos2023naturalcourseof pages 3-4) - Pediatric familial cohort: 5-year cumulative symptomatic hemorrhage risk 17.1% (higher with prior hemorrhage or CCM2 genotype). (geraldo2023naturalhistoryof pages 1-2)
2) Seizures / epilepsy (symptom) - HPO suggestions: Seizure; Epilepsy. - Frequency examples: - Familial cohort: seizures at presentation 22.7%; total ever seizure burden 32% over follow-up; new seizure disorder occurred in 7 patients. (alalfi2023clinicalpresentationhemorrhage pages 2-3) - 10-year conservatively managed cohort reported baseline cavernoma-related epilepsy 28.6%. (santos2023naturalcourseof pages 3-4) - Pediatric familial cohort: seizures at last follow-up 29.3%; refractory in 16.7% of those with seizures (2/12). (geraldo2023naturalhistoryof pages 4-5)
3) Focal neurologic deficits (clinical sign) - HPO suggestions: Focal neurological deficit; potentially Hemiparesis / Ataxia depending on location. - Strongly associated with hemorrhagic events and lesion location (e.g., brainstem/spinal); quantitative deficit rates were not extracted in the provided texts.
4) Lesion multiplicity (imaging phenotype) - HPO suggestions: Multiple cerebral cavernous malformations (verify exact term). - Examples: - 545-patient cohort: 15.0% had multiple lesions. (gillespie2023predictorsoffuture pages 1-2) - 10-year cohort: multiple CM in 49.5%; familial disease in 28.6%. (santos2023naturalcourseof pages 2-3)
Familial CCM can present in childhood; pediatric familial cohort median age at presentation 7.7 years and demonstrated clinically relevant hemorrhage and seizure burden during follow-up. (geraldo2023naturalhistoryof pages 4-5) Clinical course is heterogeneous: a 10-year untreated follow-up cohort observed increasing cumulative hemorrhage probability over time, especially after bleeding at presentation and with spinal localization. (santos2023naturalcourseof pages 1-2)
Formal QoL instruments were not extracted from cohort papers in this evidence set; however, major QoL impacts are implied by hemorrhage, seizure burden, and neurologic deficits. Trials increasingly incorporate patient-reported outcomes and functional scales (e.g., CCM Health Index; mRS). (NCT05085561 chunk 1)
Familial CCM is associated with loss-of-function variants in: - KRIT1 (CCM1) - CCM2 - PDCD10 (CCM3) (min2023endothelialcellpericyteinteractions pages 1-2, abdelilahseyfried2024arenaissanceof pages 1-3)
Variant classification per ACMG/AMP was referenced in a case report for KRIT1 truncation (deleterious under ACMG/AMP 2015), but population allele frequencies were not extracted here. (geraldo2023naturalhistoryof pages 1-2)
Somatic PIK3CA gain-of-function variants and altered MAP3K3/MEKK3 signaling are discussed as lesion drivers/accelerators in modern CCM biology. (abdelilahseyfried2024arenaissanceof pages 1-3, ayata2024roleofrhoassociated pages 1-2, shapeti2024forcemediatedangiogenesislinking pages 39-43)
Not specifically reported in extracted evidence.
Direct environmental toxicant/radiation exposures were not comprehensively extracted. A 2023 review notes prior radiotherapy is associated with increased CCM prevalence (reported as a 6-fold increase in that review), supporting radiation-induced CCM as a distinct context. (montagnoli2023therapeuticperspectiveson pages 2-4) Lifestyle/microbiome axis: biomarker studies link cavernous angioma/CCM to a permissive gut microbiome and “leaky gut” concept with inflammatory signaling (TLR4–MEKK3–KLF2/4) proposed to influence disease activity. (srinath2023plasmametaboliteswith pages 1-2, srinath2023plasmametaboliteswith pages 11-13)
Initiating genetic lesions (germline CCM gene LOF ± somatic “second hit,” sometimes with additional somatic “third-hit” drivers) lead to endothelial signaling dysregulation. This includes gain/overactivation of MEKK3–MEK5–ERK5 signaling with induction of KLF2/KLF4, promoting maladaptive endothelial transcriptional programs and endothelial-to-mesenchymal transition (EndMT), with downstream barrier dysfunction and bleeding. (abdelilahseyfried2024arenaissanceof pages 1-3, ayata2024roleofrhoassociated pages 1-2, shapeti2024forcemediatedangiogenesislinking pages 39-43) In parallel, loss of CCM complex function can cause RhoA/ROCK overactivation, stress fiber formation, junction instability, and a ROCK2-associated senescence-associated secretory phenotype (SASP) characterized by inflammation, leukocyte chemotaxis, and extracellular matrix degradation. (ayata2024roleofrhoassociated pages 1-2) These processes converge on blood–brain barrier disruption, vascular hyperpermeability, hemosiderin deposition, and clinical manifestations (microbleeds, hemorrhage, seizures, focal deficits). (montagnoli2023therapeuticperspectiveson pages 2-4, montagnoli2023therapeuticperspectiveson pages 1-2)
A 2024 commentary summarizes: “Activation of MEKK3 triggers MEK5 and ERK5 signaling, which then induces expression of KLF2 and KLF4,” and “excessive KLF2/4 activation is necessary to cause CCM-like phenotypes and induce bleeding.” (abdelilahseyfried2024arenaissanceof pages 1-3) - Suggested GO biological processes: response to fluid shear stress; endothelial cell differentiation; endothelial-to-mesenchymal transition.
A 2024 review states that a common downstream process of CCM gene LOF is “overactivation of RhoA and its effector Rho-associated kinase (ROCK)” leading to “formation of stress fibers that contribute to endothelial junction instability.” (ayata2024roleofrhoassociated pages 1-2) - Suggested GO processes: actin cytoskeleton organization; regulation of endothelial barrier establishment.
A 2023 redox-focused review states that KRIT1 loss-of-function is linked to impaired redox homeostasis and increased sensitivity to oxidative stress and inflammation, and that KRIT1 helps “maintain endothelial barrier integrity by stabilizing adherens junctions and suppressing actin stress fiber formation.” (perrelli2023krit1atraffic pages 1-3) It further states there is “compelling evidence that KRIT1 deficiency exerts pleiotropic effects… by affecting key redox-sensitive molecular pathways… against oxidative stress and inflammation,” and that KRIT1 LOF phenotypes are rescuable by antioxidant compounds and pro-autophagic mTOR inhibitors (e.g., rapamycin). (perrelli2023krit1atraffic pages 6-7) - Suggested GO processes: response to oxidative stress; autophagy; inflammatory response.
A 2023 Scientific Reports study concludes: “components of the retinoic acid synthesis and degradation pathway are transcriptionally misregulated across disease models of CCM,” and that high-dose retinoic acid worsened lesions in an adult chronic mouse model, highlighting regimen sensitivity. (grdseloff2023impairedretinoicacid pages 1-2) Model-specific findings include beneficial effects in siCCM2 HUVECs and krit1 mutant zebrafish when RA levels were increased, but worsened lesion burden/hemorrhage at ~20 mg/kg/day RA dosing in chronic mouse CCM. (grdseloff2023impairedretinoicacid pages 7-9, grdseloff2023impairedretinoicacid pages 6-7) - Suggested GO process: retinoid metabolic process (explicitly enriched in the paper’s analyses). (grdseloff2023impairedretinoicacid pages 4-5)
A 2024 engineered human microvessel study reports CCM endothelial hallmarks (“overactive MEKK3 kinase and KLF2/4 transcription factor signaling”) and finds that supplementing ECM with distinct hyaluronic acid forms “inhibits pathological cell spreading and rescues barrier function,” suggesting ECM composition modulates lesion severity. (yordanov2024hyaluronicacidturnover pages 1-3) - Suggested GO process: extracellular matrix organization. - Suggested CHEBI terms: hyaluronic acid (verify CHEBI ID).
A 2023 review reports that “Ccm3 deletion in pericytes (PCs) also induces CCM lesions” and “CCM3 deletion in ECs or PCs destabilizes PC–EC associations,” via mechanisms including angiopoietin-2 exocytosis and impaired pericyte migration, linking mural cell biology to BBB instability. (min2023endothelialcellpericyteinteractions pages 1-2) - Suggested Cell Ontology terms: brain microvascular endothelial cell; pericyte.
A 2023 Communications Medicine metabolomics study identified plasma metabolites distinguishing cavernous angioma/CCM states; it reports a metabolite diagnostic score with 87.5% sensitivity and 89% specificity (metabolite-only model) and integrative multi-omic models achieving up to 85% sensitivity and 80% specificity, linking metabolites to inflammatory signaling and microbiome features. (srinath2023plasmametaboliteswith pages 7-9, srinath2023plasmametaboliteswith pages 1-2)
Familial CCM is described as autosomal dominant with incomplete penetrance, caused by germline LOF in KRIT1/CCM1, CCM2, or PDCD10/CCM3. (min2023endothelialcellpericyteinteractions pages 1-2)
A 2023 review reports prevalence 2–9 per 1,000 and incidence 5–6 new diagnoses per million adults per year, with pediatric cases comprising 25–35% of people living with CCM; familial CCM accounts for ~20% of cases in that review. (montagnoli2023therapeuticperspectiveson pages 1-2)
MRI is the primary diagnostic modality. Susceptibility-sensitive sequences (e.g., SWI/SWAN or T2*-GRE) improve detection and show characteristic “blooming” from hemosiderin. (demir2024giantintracranialcavernous pages 1-2, demir2024giantintracranialcavernous pages 2-3) A 2024 radiology review describes the classic “popcorn” lesion with a hemosiderin rim and notes classification into types (I–IV), with type IV being punctate hypointense foci best seen on SWI. (demir2024giantintracranialcavernous pages 2-3) Digital subtraction angiography is generally not recommended for CCM diagnosis except to exclude AVM. (demir2024giantintracranialcavernous pages 2-3)
Visual evidence (MRI classification and SWI blooming): Table/figure extracts from Demir et al. 2024 are provided. (demir2024giantintracranialcavernous media cdc7d79b, demir2024giantintracranialcavernous media ee42a4a3)
Familial CCM can mimic cerebral amyloid angiopathy (CAA) on susceptibility imaging; a 2024 Acta Neurochirurgica study emphasizes applying Boston criteria for CAA and proposes FCCM-specific criteria using lesion distribution and Zabramski patterns (e.g., presence of type 2 lesions in FCCM, lesion distribution ratios). (flemming2024clinicalandradiologic pages 5-7, flemming2024clinicalandradiologic pages 1-3)
The extracted literature supports confirmatory genetic testing for suspected familial CCM syndromes and diagnostic classification based on family history and/or pathogenic CCM1–3 variants, especially in pediatric FCCM cohorts and in FCCM-vs-CAA diagnostic frameworks. (geraldo2023naturalhistoryof pages 1-2, flemming2024clinicalandradiologic pages 7-9)
Prognosis is driven by hemorrhage recurrence risk, lesion location, and seizure burden. - In a 545-patient cohort, eloquent location (HR 2.63) and symptomatic hemorrhage at presentation (HR 5.37) strongly predicted future symptomatic hemorrhage. (gillespie2023predictorsoffuture pages 1-2) - In a complete 10-year follow-up cohort, spinal localization and hemorrhage at diagnosis independently predicted (re)hemorrhage; 10-year cumulative bleeding risk was 30% overall and 67% for intramedullary spinal lesions. (santos2023naturalcourseof pages 1-2, santos2023naturalcourseof pages 3-4)
A 2023 review notes there is “no cure” and that surgical treatment is typically recommended only for superficial cortical lesions, reflecting practical constraints/risks for deeply seated lesions. (montagnoli2023therapeuticperspectiveson pages 1-2)
There is no FDA- or EU-approved pharmacologic treatment for CCM noted in recent mechanistic reviews; ROCK is a key proposed target with both direct inhibitors (e.g., fasudil) and indirect inhibitors (e.g., statins) showing preclinical efficacy, and clinical studies underway/planned. (ayata2024roleofrhoassociated pages 1-2)
Key interventional trials captured from ClinicalTrials.gov include: - REC-994 Phase 2 trial in symptomatic CCM (NCT05085561) evaluating safety and MRI/clinical outcomes. (NCT05085561 chunk 1) - Atorvastatin (AT CASH EPOC) randomized Phase I/II trial (NCT02603328) using QSM as a primary endpoint and permeability/mRS/QoL and ROCK activity as secondary endpoints; results were posted on ClinicalTrials.gov in 2025. (NCT02603328 chunk 1) - Propranolol (Treat_CCM; NCT03589014) Phase 2 pilot in familial CCM; a separate preoperative propranolol molecular-response trial (NCT03474614) was terminated due to lack of accrual. (NCT03589014 chunk 2, NCT03474614 chunk 1)
Suggested MAXO terms (examples; verify IDs): microsurgical resection; stereotactic radiosurgery; magnetic resonance imaging; genetic testing; statin therapy; beta-adrenergic receptor antagonist therapy.
No established primary prevention exists for inherited CCM beyond genetic counseling and avoidance of modifiable risk exposures when evidence supports risk. - Secondary/tertiary prevention focuses on surveillance and risk reduction (e.g., MRI monitoring; counseling about medications that may increase hemorrhage risk). - Given observed association of hormone therapy with hemorrhage risk, counseling about oral contraceptives/menopausal hormone therapy may be clinically relevant in women with CCM. (zuurbier2023femalehormonetherapy pages 3-5)
The extracted evidence focuses on experimental models rather than naturally occurring veterinary disease; no OMIA/animal natural disease evidence was retrieved.
The following structured tables can be used to populate a disease knowledge base entry.
| Entity | Identifier | Common synonyms / nomenclature | Brief pathology definition |
|---|---|---|---|
| Cerebral cavernous malformation | MONDO:0000820 | cerebral cavernous malformation; cavernous malformation; cavernoma; cavernous angioma; cavernous hemangioma; capillary-venous cavernoma (shapeti2024forcemediatedangiogenesislinking pages 39-43, min2023endothelialcellpericyteinteractions pages 1-2, montagnoli2023therapeuticperspectiveson pages 2-4, montagnoli2023therapeuticperspectiveson pages 1-2) | Low-flow cerebrovascular lesion composed of thin-walled, dilated capillary/capillary-venous channels lined by a single endothelial layer, lacking intervening brain parenchyma and typically deficient in smooth muscle/pericytes with defective/discontinuous basal lamina and a leaky blood-brain barrier prone to edema and hemorrhage (min2023endothelialcellpericyteinteractions pages 1-2, montagnoli2023therapeuticperspectiveson pages 2-4, montagnoli2023therapeuticperspectiveson pages 1-2) |
| Familial cerebral cavernous malformations | MONDO:0031037 | familial cerebral cavernous malformation; familial CCM; FCCM; familial cavernous malformation syndrome (min2023endothelialcellpericyteinteractions pages 1-2, flemming2024clinicalandradiologic pages 1-3) | Inherited form of CCM, usually autosomal dominant, characterized by multiple hemorrhagic cavernous lesions with the same core pathology as CCM and often greater lesion multiplicity/burden (min2023endothelialcellpericyteinteractions pages 1-2, flemming2024clinicalandradiologic pages 1-3, flemming2024clinicalandradiologic pages 7-9) |
| Cerebral cavernous malformation 1 | MONDO:0020724 | CCM1; KRIT1-related cerebral cavernous malformation; cerebral cavernous malformation 1 (abdelilahseyfried2024arenaissanceof pages 1-3, min2023endothelialcellpericyteinteractions pages 1-2) | Gene-defined Mendelian subtype caused by KRIT1 loss-of-function; lesions share the canonical CCM histology of dilated endothelial caverns with barrier failure and hemorrhagic tendency (abdelilahseyfried2024arenaissanceof pages 1-3, min2023endothelialcellpericyteinteractions pages 1-2, perrelli2023krit1atraffic pages 1-3) |
| Cavernous angioma with symptomatic hemorrhage | No MONDO ID established in retrieved evidence | CASH; cavernous angioma with symptomatic hemorrhage; symptomatic hemorrhagic CCM subgroup (srinath2023plasmametaboliteswith pages 7-9, srinath2023plasmametaboliteswith pages 2-3, srinath2023plasmametaboliteswith pages 1-2) | Clinical state referring to CCM/cavernous angioma patients with recent symptomatic lesional bleeding; used particularly in biomarker and trial-readiness studies rather than as a separate pathology entity (srinath2023plasmametaboliteswith pages 7-9, srinath2023plasmametaboliteswith pages 2-3, srinath2023plasmametaboliteswith pages 1-2) |
Table: This table summarizes the main disease identifiers, synonyms, and pathology wording for cerebral cavernous malformation and closely related named entities. It is useful for standardizing terminology in a disease knowledge base and linking general CCM, familial CCM, CCM1, and the CASH clinical subgroup.
| Gene / concept | Role in CCM genetics | Inheritance / penetrance | Typical pathogenic mechanism | Example variant(s) from retrieved studies | Somatic / clonal notes | URL / DOI | Evidence |
|---|---|---|---|---|---|---|---|
| KRIT1 (CCM1) | One of the 3 core Mendelian familial CCM genes; recent reviews state inherited CCM is caused by loss-of-function variants in CCM1/KRIT1, CCM2, CCM3/PDCD10 (abdelilahseyfried2024arenaissanceof pages 1-3, min2023endothelialcellpericyteinteractions pages 1-2) | Autosomal dominant with incomplete penetrance in familial CCM (min2023endothelialcellpericyteinteractions pages 1-2) | Predominantly loss-of-function with truncating consequences; KRIT1 loss destabilizes endothelial junction/barrier programs and is central to CCM pathogenesis (perrelli2023krit1atraffic pages 1-3, perrelli2023krit1atraffic pages 3-4) | c.1119dupT, p.L374Sfs*9 — frameshift, predicted truncated KRIT1 protein of 381 aa; c.1159C>T, p.Q387X — nonsense, premature termination/truncation (variant examples reported in Chinese familial CCM and hereditary CCM studies) | Familial lesions fit a two-hit model with germline KRIT1 loss plus somatic biallelic loss in lesion-forming endothelial cells/clones (shapeti2024forcemediatedangiogenesislinking pages 39-43, min2023endothelialcellpericyteinteractions pages 1-2, yordanov2024hyaluronicacidturnover pages 14-14) | https://doi.org/10.3389/fnins.2023.1184333 ; https://doi.org/10.3389/fonc.2023.1141488 | (abdelilahseyfried2024arenaissanceof pages 1-3, min2023endothelialcellpericyteinteractions pages 1-2, perrelli2023krit1atraffic pages 1-3, perrelli2023krit1atraffic pages 3-4) |
| CCM2 | Core Mendelian familial CCM gene; part of the CCM protein complex regulating endothelial signaling (abdelilahseyfried2024arenaissanceof pages 1-3, min2023endothelialcellpericyteinteractions pages 1-2) | Autosomal dominant with incomplete penetrance in familial CCM (min2023endothelialcellpericyteinteractions pages 1-2) | Predominantly loss-of-function; CCM2 deficiency contributes to CCM via dysregulated MEKK3-KLF2/4 and related endothelial programs (min2023endothelialcellpericyteinteractions pages 1-2, grdseloff2023impairedretinoicacid pages 2-3) | No specific example variant retrieved in the provided evidence set | Familial disease aligns with germline + somatic second-hit biology; acute/chronic Ccm2 mouse and endothelial models support lesion formation after CCM2 loss (min2023endothelialcellpericyteinteractions pages 1-2, grdseloff2023impairedretinoicacid pages 2-3, grdseloff2023impairedretinoicacid pages 6-7) | https://doi.org/10.1101/cshperspect.a041188 ; https://doi.org/10.1038/s41598-023-31905-0 | (min2023endothelialcellpericyteinteractions pages 1-2, grdseloff2023impairedretinoicacid pages 2-3, grdseloff2023impairedretinoicacid pages 6-7) |
| PDCD10 (CCM3) | Third core Mendelian familial CCM gene; associated with CCM and often emphasized as capable of severe phenotypes in models (min2023endothelialcellpericyteinteractions pages 1-2) | Autosomal dominant with incomplete penetrance in familial CCM (min2023endothelialcellpericyteinteractions pages 1-2) | Predominantly loss-of-function; CCM3 loss disrupts endothelial/pericyte interactions, BBB stability, and lesion biology (min2023endothelialcellpericyteinteractions pages 1-2) | No specific example variant retrieved in the provided evidence set | Somatic biallelic loss and clonal expansion are implicated; endothelial or pericyte Ccm3/Pdcd10 deletion can induce lesions in models (min2023endothelialcellpericyteinteractions pages 1-2) | https://doi.org/10.1101/cshperspect.a041188 | (min2023endothelialcellpericyteinteractions pages 1-2) |
| Two-hit mechanism | Current model for familial CCM lesion genesis: inherited pathogenic variant in a CCM gene plus somatic loss of the remaining allele in susceptible cells | Applies to familial CCM; inherited first hit followed by lesion-specific second hit | Produces biallelic loss of CCM gene function in lesion-forming endothelium | Not a single variant; mechanism supported across CCM genes | Supported by mouse and human lesion studies; endothelial clonal expansion is part of lesion development (shapeti2024forcemediatedangiogenesislinking pages 39-43, min2023endothelialcellpericyteinteractions pages 1-2, yordanov2024hyaluronicacidturnover pages 14-14) | https://doi.org/10.1101/cshperspect.a041188 ; https://doi.org/10.1063/5.0159330 | (shapeti2024forcemediatedangiogenesislinking pages 39-43, min2023endothelialcellpericyteinteractions pages 1-2, yordanov2024hyaluronicacidturnover pages 14-14) |
| Additional somatic driver: PIK3CA GOF | Recent work/reviews identify somatic gain-of-function PIK3CA variants in sporadic/aggressive CCM biology, often co-occurring with CCM loss-of-function alleles (abdelilahseyfried2024arenaissanceof pages 1-3, shapeti2024forcemediatedangiogenesislinking pages 39-43, ayata2024roleofrhoassociated pages 1-2) | Not inherited Mendelian driver in classic familial CCM; somatic lesion-associated driver | Gain-of-function activating PI3K signaling; linked to lesion growth and hemorrhage risk (ayata2024roleofrhoassociated pages 1-2, abdelilahseyfried2024arenaissanceof pages 1-3) | Specific PIK3CA variant not provided in extracted evidence | Proposed as a third-hit / cooperating driver that can fuel cavernoma growth together with CCM loss (shapeti2024forcemediatedangiogenesislinking pages 39-43, abdelilahseyfried2024arenaissanceof pages 1-3) | https://doi.org/10.1038/s44161-024-00504-1 ; https://doi.org/10.1212/nxg.0000000000200121 | (abdelilahseyfried2024arenaissanceof pages 1-3, shapeti2024forcemediatedangiogenesislinking pages 39-43, ayata2024roleofrhoassociated pages 1-2) |
| Additional somatic driver: MAP3K3 / MEKK3 GOF | Recent literature notes MAP3K3 (MEKK3) gain-of-function as another somatic driver relevant to CCM pathogenesis (abdelilahseyfried2024arenaissanceof pages 1-3, shapeti2024forcemediatedangiogenesislinking pages 46-49) | Somatic rather than classic familial inherited driver | Gain-of-function with activation of MEKK3-MEK5-ERK5-KLF2/4 and downstream CCM-like signaling (abdelilahseyfried2024arenaissanceof pages 1-3, shapeti2024forcemediatedangiogenesislinking pages 46-49) | Specific MAP3K3 variant not available in extracted evidence | Reported as potentially sufficient to initiate lesions even without CCM loss in some contexts; also intersects PI3K-mTOR signaling (shapeti2024forcemediatedangiogenesislinking pages 39-43, shapeti2024forcemediatedangiogenesislinking pages 46-49) | https://doi.org/10.1038/s44161-024-00504-1 | (abdelilahseyfried2024arenaissanceof pages 1-3, shapeti2024forcemediatedangiogenesislinking pages 39-43, shapeti2024forcemediatedangiogenesislinking pages 46-49) |
Table: This table summarizes the core Mendelian CCM genes, their inheritance and loss-of-function pattern, the two-hit lesion model, and newer somatic drivers such as PIK3CA and MAP3K3. It also includes example KRIT1 truncating variants reported in recent retrieved studies with DOI links.
| Study | Population | N | Follow-up | Hemorrhage rate / cumulative risk | Seizure data | Key prognostic factors | URL / DOI |
|---|---|---|---|---|---|---|---|
| Gillespie 2023, Neurosurgical Review | Mixed adult CCM cohort (mostly sporadic/clinical referral cohort) | 545 patients; 734 lesions | Median 46 months (IQR 19–85) | Annual symptomatic hemorrhage rate 1.00% per lesion-year (25 events/2512 lesion-years); 1.50% per lesion-year in symptomatic-at-presentation vs 0.29% in non-symptomatic-at-presentation | Not reported in extracted evidence | Larger lesion size HR 1.04 (95% CI 1.01–1.07); eloquent location HR 2.63 (95% CI 1.12–6.16); symptomatic hemorrhage at presentation HR 5.37 (95% CI 2.40–11.99) (gillespie2023predictorsoffuture pages 1-2) | https://doi.org/10.1007/s10143-023-01949-x |
| Santos 2023, Scientific Reports | Conservatively managed cerebral and spinal cavernous malformations | 91 | Complete 10-year follow-up; 910 person-years | Overall 10-year cumulative hemorrhage risk 30% (95% CI 21–40%); annual (re)hemorrhage 3.5% (32/910 person-years); subgroup annual rates: bleeding at presentation 4.5%, brainstem 4.1%, spinal 6.7%, familial 3.8%, asymptomatic 0%; subgroup 10-year cumulative risk: spinal 67%, brainstem 33%, familial 31%, asymptomatic 0% (santos2023naturalcourseof pages 2-3, santos2023naturalcourseof pages 3-4, santos2023naturalcourseof pages 1-2) | Baseline cavernoma-related epilepsy 26/91 (28.6%); no prospective seizure rate extracted (santos2023naturalcourseof pages 2-3, santos2023naturalcourseof pages 3-4) | Hemorrhage at diagnosis aOR 2.41, aHR 2.31; spinal localization aOR 4.20, aHR 3.91; also reported as predictors in adjusted models p=0.039 and p=0.010, remaining significant in Cox regression p=0.049 and p=0.016 (santos2023naturalcourseof pages 3-4, santos2023naturalcourseof pages 1-2) | https://doi.org/10.1038/s41598-023-42594-0 |
| Geraldo 2023, Neuroradiology | Pediatric familial CCM (FCCM) multicenter cohort | 41 | 140.5 person-years; median 54.3 months (range 4.0–205.4) | Seven symptomatic hemorrhages during follow-up; annual hemorrhage rate 5.0% per person-year; cumulative symptomatic hemorrhage risk 7.3% at 1 year, 14.6% at 2 years, 17.1% at 5 years; 5-year risk higher with prior symptomatic hemorrhage 33.3%, CCM2 genotype 33.3%, positive family history 20.7% (geraldo2023naturalhistoryof pages 1-2, geraldo2023naturalhistoryof pages 4-5) | Seizures at last follow-up in 12/41 (29.3%); 10/12 medically controlled, 2/12 refractory; one death (2.4%) from sudden unexpected death in refractory epilepsy (geraldo2023naturalhistoryof pages 4-5) | Number of brainstem CCM at first MRI adjusted HR 1.37 (P=0.005); number of posterior fossa CCM adjusted HR 1.64 (P=0.004) (geraldo2023naturalhistoryof pages 1-2) | https://doi.org/10.1007/s00234-022-03056-y |
| Alalfi 2023, Journal of Neurosurgery | Familial cavernous malformation (FCM) prospective cohort | 75 | Median 9.9 years total follow-up; 949.2 patient-years; censored hemorrhage analysis 739.9 patient-years | First prospective hemorrhage rate 4.0% per patient-year; 30 patients had first prospective hemorrhage at median 5.3 years after diagnosis (alalfi2023clinicalpresentationhemorrhage pages 2-3) | 17/75 (22.7%) had seizures at presentation; 7 developed new seizure disorder at mean 4.3 years; total ever-seizure burden 24/75 (32%) (alalfi2023clinicalpresentationhemorrhage pages 2-3) | Kaplan–Meier comparison by hemorrhage-at-presentation performed, but no extracted HR/OR available (alalfi2023clinicalpresentationhemorrhage pages 2-3) | https://doi.org/10.3171/2023.1.jns222434 |
| Zuurbier 2023, Neurology | Female CCM cohort evaluating hormone exposure | 722 females (137 exposed; 585 unexposed) | Mean 3.33 years; 2400 person-years | Prospective intracranial hemorrhage: 46/137 (33.6%) exposed vs 91/585 (15.6%) unexposed; incidence 7.44 vs 5.11 per 100 person-years; adjusted HR for female hormone therapy 1.56 (95% CI 1.09–2.24); oral contraceptives age 10–44 adjusted HR 2.00 (95% CI 1.26–3.17); excluding transdermal users adjusted HR 1.73 (95% CI 1.20–2.50) (zuurbier2023femalehormonetherapy pages 3-5) | Not reported in extracted evidence | Menopausal hormone therapy nonsignificant in one extracted analysis: adjusted HR 1.44 (95% CI 0.68–3.05); another extracted subgroup analysis reported oral MHT adjusted HR 2.39 (95% CI 1.11–5.14); smoker-restricted oral contraceptive adjusted HR 2.71 (95% CI 1.01–7.28) (zuurbier2023femalehormonetherapy pages 3-5) | https://doi.org/10.1212/WNL.0000000000206888 |
Table: This table summarizes the main quantitative natural-history and prognostic findings from recent 2023 studies on cerebral cavernous malformation, including familial and pediatric cohorts. It is useful for comparing hemorrhage risk, seizure burden, and major prognostic factors across study populations.
| Intervention | Mechanistic rationale | NCT ID | Phase | Status | Enrollment | Primary endpoint(s) | Key secondary endpoint(s) | ClinicalTrials.gov URL | Evidence |
|---|---|---|---|---|---|---|---|---|---|
| REC-994 (oral, 200 mg QD or 400 mg QD) vs placebo | Investigational medical therapy for symptomatic CCM; trial emphasizes safety, hemorrhagic-event monitoring, lesion burden, and patient-reported/functional outcomes, consistent with a barrier-stabilization/anti-lesion strategy in symptomatic disease (NCT05085561 chunk 1) | NCT05085561 | Phase 2 | Completed | 62 | Incidence and severity of adverse events up to 24 months | MRI-confirmed cerebral hemorrhagic events; lesion size/number on MRI; Cerebral Cavernous Malformation Health Index; modified Rankin Scale; SymptoMScreen; plasma PK of REC-994 (NCT05085561 chunk 1) | https://clinicaltrials.gov/ct2/show/NCT05085561 | (NCT05085561 chunk 1) |
| Atorvastatin (40–80 mg once daily) vs placebo | Indirect ROCK-pathway modulation is a key CCM therapeutic concept; trial includes ROCK activity in peripheral blood leukocytes as a biomarker and MRI QSM/permeability readouts for lesional activity (ayata2024roleofrhoassociated pages 1-2, NCT02603328 chunk 1) | NCT02603328 | Phase 1/2 | Completed | 80 | Percent change in mean lesional QSM score over 2 years | Percent change in DCEQP lesional vascular permeability; modified Rankin Scale at years 1 and 2; EQ-VAS; compliance; mean percent change in ROCK activity in peripheral blood leukocytes (NCT02603328 chunk 1) | https://clinicaltrials.gov/ct2/show/NCT02603328 | (ayata2024roleofrhoassociated pages 1-2, NCT02603328 chunk 1) |
| Propranolol in familial CCM (Treat_CCM) | Repurposed pharmacologic therapy tested in familial CCM; trial record confirms phase 2 pilot design and later publication of safety/efficacy report, but extracted chunk does not provide endpoint details (NCT03589014 chunk 2) | NCT03589014 | Phase 2 pilot | Completed | 71 | Not specified in extracted trial chunk | Not specified in extracted trial chunk; record notes protocol and Lancet Neurology 2023 report of safety/efficacy study (NCT03589014 chunk 2) | https://clinicaltrials.gov/ct2/show/NCT03589014 | (NCT03589014 chunk 2) |
| Oral propranolol 60 mg ER daily for 7–10 days preoperatively vs control | Short-course preoperative propranolol assessed as a translational biologic-response study in symptomatic cavernous malformation tissue/blood rather than a lesion-outcome efficacy trial (NCT03474614 chunk 1) | NCT03474614 | Phase 2 | Terminated (lack of accrual) | 4 | Effect of low-dose oral propranolol on global mRNA and miRNA expression in blood and CCM tissue | Correlation of treatment response with established CCM gene mutations; adverse events related to propranolol (NCT03474614 chunk 1) | https://clinicaltrials.gov/ct2/show/NCT03474614 | (NCT03474614 chunk 1) |
Table: This table summarizes the CCM interventional trials retrieved from ClinicalTrials.gov for REC-994, atorvastatin, and propranolol. It highlights trial design, endpoints, enrollment, and mechanistic rationale relevant to current translational and clinical development.
References
(min2023endothelialcellpericyteinteractions pages 1-2): Wang Min and Jenny Huanjiao Zhou. Endothelial cell-pericyte interactions in the pathogenesis of cerebral cavernous malformations (ccms). Cold Spring Harbor perspectives in medicine, 13:a041188, Jun 2023. URL: https://doi.org/10.1101/cshperspect.a041188, doi:10.1101/cshperspect.a041188. This article has 9 citations and is from a peer-reviewed journal.
(montagnoli2023therapeuticperspectiveson pages 2-4): Tadeu L. Montagnoli, Daniela R. de Oliveira, and Carlos A. Manssour Fraga. Therapeutic perspectives on rock inhibition for cerebral cavernous malformations. Kinases and Phosphatases, 1:72-96, Feb 2023. URL: https://doi.org/10.3390/kinasesphosphatases1010006, doi:10.3390/kinasesphosphatases1010006. This article has 8 citations.
(montagnoli2023therapeuticperspectiveson pages 1-2): Tadeu L. Montagnoli, Daniela R. de Oliveira, and Carlos A. Manssour Fraga. Therapeutic perspectives on rock inhibition for cerebral cavernous malformations. Kinases and Phosphatases, 1:72-96, Feb 2023. URL: https://doi.org/10.3390/kinasesphosphatases1010006, doi:10.3390/kinasesphosphatases1010006. This article has 8 citations.
(shapeti2024forcemediatedangiogenesislinking pages 39-43): A Shapeti, H Van Oosterwyck, A Ranga, and E Faurobert. Force-mediated angiogenesis: linking mechanical mechanisms to vascular lesion growth. Unknown journal, 2024.
(abdelilahseyfried2024arenaissanceof pages 1-3): Salim Abdelilah-Seyfried and Hanjoong Jo. A renaissance of cerebral cavernous malformation proteins in vascular physiology. Nature cardiovascular research, 3 7:771-773, Jun 2024. URL: https://doi.org/10.1038/s44161-024-00504-1, doi:10.1038/s44161-024-00504-1. This article has 3 citations and is from a peer-reviewed journal.
(ayata2024roleofrhoassociated pages 1-2): Cenk Ayata, Helen Kim, Leslie Morrison, James K. Liao, Juan Gutierrez, Miguel Lopez-Toledano, Enrique Carrazana, Adrian L. Rabinowicz, and Issam A. Awad. Role of rho-associated kinase in the pathophysiology of cerebral cavernous malformations. Neurology Genetics, Feb 2024. URL: https://doi.org/10.1212/nxg.0000000000200121, doi:10.1212/nxg.0000000000200121. This article has 21 citations.
(perrelli2023krit1atraffic pages 15-16): Andrea Perrelli, Chiara Ferraris, Elisa Berni, Angela J. Glading, and Saverio Francesco Retta. Krit1: a traffic warden at the busy crossroads between redox signaling and the pathogenesis of cerebral cavernous malformation disease. Antioxidants & Redox Signaling, Nov 2023. URL: https://doi.org/10.1089/ars.2021.0263, doi:10.1089/ars.2021.0263. This article has 16 citations and is from a domain leading peer-reviewed journal.
(yordanov2024hyaluronicacidturnover pages 1-3): Teodor E. Yordanov, Marco A. E. Martinez, Tyron Esposito, Juliann B. Tefft, Larisa I. Labzin, Samantha J. Stehbens, Alan E. Rowan, Benjamin M. Hogan, Christopher S. Chen, Jan Lauko, and Anne K. Lagendijk. Hyaluronic acid turnover controls the severity of cerebral cavernous malformations in bioengineered human micro-vessels. APL Bioengineering, Oct 2024. URL: https://doi.org/10.1063/5.0159330, doi:10.1063/5.0159330. This article has 5 citations.
(srinath2023plasmametaboliteswith pages 2-3): Abhinav Srinath, Bingqing Xie, Ying Li, Je Yeong Sone, Sharbel Romanos, Chang Chen, Anukriti Sharma, Sean Polster, Pieter C. Dorrestein, Kelly C. Weldon, Dorothy DeBiasse, Thomas Moore, Rhonda Lightle, Janne Koskimäki, Dongdong Zhang, Agnieszka Stadnik, Kristina Piedad, Matthew Hagan, Abdallah Shkoukani, Julián Carrión-Penagos, Dehua Bi, Le Shen, Robert Shenkar, Yuan Ji, Ashley Sidebottom, Eric Pamer, Jack A. Gilbert, Mark L. Kahn, Mark D’Souza, Dinanath Sulakhe, Issam A. Awad, and Romuald Girard. Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma. Communications Medicine, Mar 2023. URL: https://doi.org/10.1038/s43856-023-00265-1, doi:10.1038/s43856-023-00265-1. This article has 19 citations and is from a peer-reviewed journal.
(NCT02603328 chunk 1): Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. University of Chicago. 2018. ClinicalTrials.gov Identifier: NCT02603328
(srinath2023plasmametaboliteswith pages 1-2): Abhinav Srinath, Bingqing Xie, Ying Li, Je Yeong Sone, Sharbel Romanos, Chang Chen, Anukriti Sharma, Sean Polster, Pieter C. Dorrestein, Kelly C. Weldon, Dorothy DeBiasse, Thomas Moore, Rhonda Lightle, Janne Koskimäki, Dongdong Zhang, Agnieszka Stadnik, Kristina Piedad, Matthew Hagan, Abdallah Shkoukani, Julián Carrión-Penagos, Dehua Bi, Le Shen, Robert Shenkar, Yuan Ji, Ashley Sidebottom, Eric Pamer, Jack A. Gilbert, Mark L. Kahn, Mark D’Souza, Dinanath Sulakhe, Issam A. Awad, and Romuald Girard. Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma. Communications Medicine, Mar 2023. URL: https://doi.org/10.1038/s43856-023-00265-1, doi:10.1038/s43856-023-00265-1. This article has 19 citations and is from a peer-reviewed journal.
(perrelli2023krit1atraffic pages 1-3): Andrea Perrelli, Chiara Ferraris, Elisa Berni, Angela J. Glading, and Saverio Francesco Retta. Krit1: a traffic warden at the busy crossroads between redox signaling and the pathogenesis of cerebral cavernous malformation disease. Antioxidants & Redox Signaling, Nov 2023. URL: https://doi.org/10.1089/ars.2021.0263, doi:10.1089/ars.2021.0263. This article has 16 citations and is from a domain leading peer-reviewed journal.
(gillespie2023predictorsoffuture pages 1-2): Conor S. Gillespie, Khalifa E. Alnaham, George E. Richardson, Mohammad A. Mustafa, Basel A. Taweel, Abdurrahman I. Islim, Cathal John Hannan, and Emmanuel Chavredakis. Predictors of future haemorrhage from cerebral cavernous malformations: a retrospective cohort study. Neurosurgical Review, Feb 2023. URL: https://doi.org/10.1007/s10143-023-01949-x, doi:10.1007/s10143-023-01949-x. This article has 8 citations and is from a peer-reviewed journal.
(santos2023naturalcourseof pages 3-4): Alejandro N. Santos, Laurèl Rauschenbach, Hanah H. Gull, Angelina Olbrich, Thiemo F. Dinger, Marvin Darkwah Oppong, Christoph Rieß, Bixia Chen, Annika Lenkeit, Börge Schmidt, Yan Li, Ramazan Jabbarli, Karsten H. Wrede, Adrian Siegel, Ulrich Sure, and Philipp Dammann. Natural course of cerebral and spinal cavernous malformations: a complete ten-year follow-up study. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-42594-0, doi:10.1038/s41598-023-42594-0. This article has 15 citations and is from a peer-reviewed journal.
(alalfi2023clinicalpresentationhemorrhage pages 2-3): Mohammed O. Alalfi, Giuseppe Lanzino, and Kelly D. Flemming. Clinical presentation, hemorrhage risk, and outcome in patients with familial cavernous malformations: a pragmatic prospective analysis of 75 patients. Journal of Neurosurgery, 139:1018-1024, Oct 2023. URL: https://doi.org/10.3171/2023.1.jns222434, doi:10.3171/2023.1.jns222434. This article has 17 citations and is from a domain leading peer-reviewed journal.
(zuurbier2023femalehormonetherapy pages 3-5): Susanna M. Zuurbier, Alejandro N. Santos, Kelly D. Flemming, Börge Schmidt, Ramazan Jabbarli, Giuseppe Lanzino, Ulrich Sure, and Philipp Dammann. Female hormone therapy and risk of intracranial hemorrhage from cerebral cavernous malformations. Neurology, Apr 2023. URL: https://doi.org/10.1212/wnl.0000000000206888, doi:10.1212/wnl.0000000000206888. This article has 31 citations and is from a highest quality peer-reviewed journal.
(grdseloff2023impairedretinoicacid pages 4-5): Nastasja Grdseloff, Gwenola Boulday, Claudia J. Rödel, Cécile Otten, Daphné Raphaelle Vannier, Cécile Cardoso, Eva Faurobert, Deepika Dogra, Elisabeth Tournier-Lasserve, and Salim Abdelilah-Seyfried. Impaired retinoic acid signaling in cerebral cavernous malformations. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-31905-0, doi:10.1038/s41598-023-31905-0. This article has 4 citations and is from a peer-reviewed journal.
(grdseloff2023impairedretinoicacid pages 6-7): Nastasja Grdseloff, Gwenola Boulday, Claudia J. Rödel, Cécile Otten, Daphné Raphaelle Vannier, Cécile Cardoso, Eva Faurobert, Deepika Dogra, Elisabeth Tournier-Lasserve, and Salim Abdelilah-Seyfried. Impaired retinoic acid signaling in cerebral cavernous malformations. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-31905-0, doi:10.1038/s41598-023-31905-0. This article has 4 citations and is from a peer-reviewed journal.
(NCT05085561 chunk 1): The Symptomatic Cerebral Cavernous Malformation Trial of REC-994. Recursion Pharmaceuticals Inc.. 2022. ClinicalTrials.gov Identifier: NCT05085561
(NCT03589014 chunk 2): Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation. Mario Negri Institute for Pharmacological Research. 2018. ClinicalTrials.gov Identifier: NCT03589014
(geraldo2023naturalhistoryof pages 1-2): Ana Filipa Geraldo, Cesar Augusto P. F. Alves, Aysha Luis, Domenico Tortora, Joana Guimarães, Daisy Abreu, Sofia Reimão, Marco Pavanello, Patrizia de Marco, Marcello Scala, Valeria Capra, Rui Vaz, Andrea Rossi, Erin Simon Schwartz, Kshitij Mankad, and Mariasavina Severino. Natural history of familial cerebral cavernous malformation syndrome in children: a multicenter cohort study. Neuroradiology, 65:401-414, Oct 2023. URL: https://doi.org/10.1007/s00234-022-03056-y, doi:10.1007/s00234-022-03056-y. This article has 17 citations and is from a peer-reviewed journal.
(srinath2023plasmametaboliteswith pages 11-13): Abhinav Srinath, Bingqing Xie, Ying Li, Je Yeong Sone, Sharbel Romanos, Chang Chen, Anukriti Sharma, Sean Polster, Pieter C. Dorrestein, Kelly C. Weldon, Dorothy DeBiasse, Thomas Moore, Rhonda Lightle, Janne Koskimäki, Dongdong Zhang, Agnieszka Stadnik, Kristina Piedad, Matthew Hagan, Abdallah Shkoukani, Julián Carrión-Penagos, Dehua Bi, Le Shen, Robert Shenkar, Yuan Ji, Ashley Sidebottom, Eric Pamer, Jack A. Gilbert, Mark L. Kahn, Mark D’Souza, Dinanath Sulakhe, Issam A. Awad, and Romuald Girard. Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma. Communications Medicine, Mar 2023. URL: https://doi.org/10.1038/s43856-023-00265-1, doi:10.1038/s43856-023-00265-1. This article has 19 citations and is from a peer-reviewed journal.
(geraldo2023naturalhistoryof pages 4-5): Ana Filipa Geraldo, Cesar Augusto P. F. Alves, Aysha Luis, Domenico Tortora, Joana Guimarães, Daisy Abreu, Sofia Reimão, Marco Pavanello, Patrizia de Marco, Marcello Scala, Valeria Capra, Rui Vaz, Andrea Rossi, Erin Simon Schwartz, Kshitij Mankad, and Mariasavina Severino. Natural history of familial cerebral cavernous malformation syndrome in children: a multicenter cohort study. Neuroradiology, 65:401-414, Oct 2023. URL: https://doi.org/10.1007/s00234-022-03056-y, doi:10.1007/s00234-022-03056-y. This article has 17 citations and is from a peer-reviewed journal.
(santos2023naturalcourseof pages 2-3): Alejandro N. Santos, Laurèl Rauschenbach, Hanah H. Gull, Angelina Olbrich, Thiemo F. Dinger, Marvin Darkwah Oppong, Christoph Rieß, Bixia Chen, Annika Lenkeit, Börge Schmidt, Yan Li, Ramazan Jabbarli, Karsten H. Wrede, Adrian Siegel, Ulrich Sure, and Philipp Dammann. Natural course of cerebral and spinal cavernous malformations: a complete ten-year follow-up study. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-42594-0, doi:10.1038/s41598-023-42594-0. This article has 15 citations and is from a peer-reviewed journal.
(santos2023naturalcourseof pages 1-2): Alejandro N. Santos, Laurèl Rauschenbach, Hanah H. Gull, Angelina Olbrich, Thiemo F. Dinger, Marvin Darkwah Oppong, Christoph Rieß, Bixia Chen, Annika Lenkeit, Börge Schmidt, Yan Li, Ramazan Jabbarli, Karsten H. Wrede, Adrian Siegel, Ulrich Sure, and Philipp Dammann. Natural course of cerebral and spinal cavernous malformations: a complete ten-year follow-up study. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-42594-0, doi:10.1038/s41598-023-42594-0. This article has 15 citations and is from a peer-reviewed journal.
(perrelli2023krit1atraffic pages 6-7): Andrea Perrelli, Chiara Ferraris, Elisa Berni, Angela J. Glading, and Saverio Francesco Retta. Krit1: a traffic warden at the busy crossroads between redox signaling and the pathogenesis of cerebral cavernous malformation disease. Antioxidants & Redox Signaling, Nov 2023. URL: https://doi.org/10.1089/ars.2021.0263, doi:10.1089/ars.2021.0263. This article has 16 citations and is from a domain leading peer-reviewed journal.
(grdseloff2023impairedretinoicacid pages 1-2): Nastasja Grdseloff, Gwenola Boulday, Claudia J. Rödel, Cécile Otten, Daphné Raphaelle Vannier, Cécile Cardoso, Eva Faurobert, Deepika Dogra, Elisabeth Tournier-Lasserve, and Salim Abdelilah-Seyfried. Impaired retinoic acid signaling in cerebral cavernous malformations. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-31905-0, doi:10.1038/s41598-023-31905-0. This article has 4 citations and is from a peer-reviewed journal.
(grdseloff2023impairedretinoicacid pages 7-9): Nastasja Grdseloff, Gwenola Boulday, Claudia J. Rödel, Cécile Otten, Daphné Raphaelle Vannier, Cécile Cardoso, Eva Faurobert, Deepika Dogra, Elisabeth Tournier-Lasserve, and Salim Abdelilah-Seyfried. Impaired retinoic acid signaling in cerebral cavernous malformations. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-31905-0, doi:10.1038/s41598-023-31905-0. This article has 4 citations and is from a peer-reviewed journal.
(srinath2023plasmametaboliteswith pages 7-9): Abhinav Srinath, Bingqing Xie, Ying Li, Je Yeong Sone, Sharbel Romanos, Chang Chen, Anukriti Sharma, Sean Polster, Pieter C. Dorrestein, Kelly C. Weldon, Dorothy DeBiasse, Thomas Moore, Rhonda Lightle, Janne Koskimäki, Dongdong Zhang, Agnieszka Stadnik, Kristina Piedad, Matthew Hagan, Abdallah Shkoukani, Julián Carrión-Penagos, Dehua Bi, Le Shen, Robert Shenkar, Yuan Ji, Ashley Sidebottom, Eric Pamer, Jack A. Gilbert, Mark L. Kahn, Mark D’Souza, Dinanath Sulakhe, Issam A. Awad, and Romuald Girard. Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma. Communications Medicine, Mar 2023. URL: https://doi.org/10.1038/s43856-023-00265-1, doi:10.1038/s43856-023-00265-1. This article has 19 citations and is from a peer-reviewed journal.
(demir2024giantintracranialcavernous pages 1-2): Mustafa Kemal Demir, Deniz Kılıc, Emre Zorlu, and Turker Kılıc. Giant intracranial cavernous malformations: a review on magnetic resonance imaging characteristics. Indian Journal of Radiology and Imaging, 34:511-521, Feb 2024. URL: https://doi.org/10.1055/s-0044-1779587, doi:10.1055/s-0044-1779587. This article has 4 citations.
(demir2024giantintracranialcavernous pages 2-3): Mustafa Kemal Demir, Deniz Kılıc, Emre Zorlu, and Turker Kılıc. Giant intracranial cavernous malformations: a review on magnetic resonance imaging characteristics. Indian Journal of Radiology and Imaging, 34:511-521, Feb 2024. URL: https://doi.org/10.1055/s-0044-1779587, doi:10.1055/s-0044-1779587. This article has 4 citations.
(demir2024giantintracranialcavernous media cdc7d79b): Mustafa Kemal Demir, Deniz Kılıc, Emre Zorlu, and Turker Kılıc. Giant intracranial cavernous malformations: a review on magnetic resonance imaging characteristics. Indian Journal of Radiology and Imaging, 34:511-521, Feb 2024. URL: https://doi.org/10.1055/s-0044-1779587, doi:10.1055/s-0044-1779587. This article has 4 citations.
(demir2024giantintracranialcavernous media ee42a4a3): Mustafa Kemal Demir, Deniz Kılıc, Emre Zorlu, and Turker Kılıc. Giant intracranial cavernous malformations: a review on magnetic resonance imaging characteristics. Indian Journal of Radiology and Imaging, 34:511-521, Feb 2024. URL: https://doi.org/10.1055/s-0044-1779587, doi:10.1055/s-0044-1779587. This article has 4 citations.
(flemming2024clinicalandradiologic pages 5-7): KD Flemming, Jonathan Graff Radford, Ross Reichard, James Klaas, Sherri Braksick, Petrice Cogswell, and Giuseppe Lanzino. Clinical and radiologic distinctions between familial cavernous malformation syndrome and cerebral amyloid angiopathy. Acta Neurochirurgica, Dec 2024. URL: https://doi.org/10.1007/s00701-024-06400-8, doi:10.1007/s00701-024-06400-8. This article has 0 citations and is from a peer-reviewed journal.
(flemming2024clinicalandradiologic pages 1-3): KD Flemming, Jonathan Graff Radford, Ross Reichard, James Klaas, Sherri Braksick, Petrice Cogswell, and Giuseppe Lanzino. Clinical and radiologic distinctions between familial cavernous malformation syndrome and cerebral amyloid angiopathy. Acta Neurochirurgica, Dec 2024. URL: https://doi.org/10.1007/s00701-024-06400-8, doi:10.1007/s00701-024-06400-8. This article has 0 citations and is from a peer-reviewed journal.
(flemming2024clinicalandradiologic pages 7-9): KD Flemming, Jonathan Graff Radford, Ross Reichard, James Klaas, Sherri Braksick, Petrice Cogswell, and Giuseppe Lanzino. Clinical and radiologic distinctions between familial cavernous malformation syndrome and cerebral amyloid angiopathy. Acta Neurochirurgica, Dec 2024. URL: https://doi.org/10.1007/s00701-024-06400-8, doi:10.1007/s00701-024-06400-8. This article has 0 citations and is from a peer-reviewed journal.
(NCT03474614 chunk 1): Lori Wood. Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation. St. Joseph's Hospital and Medical Center, Phoenix. 2018. ClinicalTrials.gov Identifier: NCT03474614
(grdseloff2023impairedretinoicacid pages 5-6): Nastasja Grdseloff, Gwenola Boulday, Claudia J. Rödel, Cécile Otten, Daphné Raphaelle Vannier, Cécile Cardoso, Eva Faurobert, Deepika Dogra, Elisabeth Tournier-Lasserve, and Salim Abdelilah-Seyfried. Impaired retinoic acid signaling in cerebral cavernous malformations. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-31905-0, doi:10.1038/s41598-023-31905-0. This article has 4 citations and is from a peer-reviewed journal.
(perrelli2023krit1atraffic pages 3-4): Andrea Perrelli, Chiara Ferraris, Elisa Berni, Angela J. Glading, and Saverio Francesco Retta. Krit1: a traffic warden at the busy crossroads between redox signaling and the pathogenesis of cerebral cavernous malformation disease. Antioxidants & Redox Signaling, Nov 2023. URL: https://doi.org/10.1089/ars.2021.0263, doi:10.1089/ars.2021.0263. This article has 16 citations and is from a domain leading peer-reviewed journal.
(yordanov2024hyaluronicacidturnover pages 14-14): Teodor E. Yordanov, Marco A. E. Martinez, Tyron Esposito, Juliann B. Tefft, Larisa I. Labzin, Samantha J. Stehbens, Alan E. Rowan, Benjamin M. Hogan, Christopher S. Chen, Jan Lauko, and Anne K. Lagendijk. Hyaluronic acid turnover controls the severity of cerebral cavernous malformations in bioengineered human micro-vessels. APL Bioengineering, Oct 2024. URL: https://doi.org/10.1063/5.0159330, doi:10.1063/5.0159330. This article has 5 citations.
(grdseloff2023impairedretinoicacid pages 2-3): Nastasja Grdseloff, Gwenola Boulday, Claudia J. Rödel, Cécile Otten, Daphné Raphaelle Vannier, Cécile Cardoso, Eva Faurobert, Deepika Dogra, Elisabeth Tournier-Lasserve, and Salim Abdelilah-Seyfried. Impaired retinoic acid signaling in cerebral cavernous malformations. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-31905-0, doi:10.1038/s41598-023-31905-0. This article has 4 citations and is from a peer-reviewed journal.
(shapeti2024forcemediatedangiogenesislinking pages 46-49): A Shapeti, H Van Oosterwyck, A Ranga, and E Faurobert. Force-mediated angiogenesis: linking mechanical mechanisms to vascular lesion growth. Unknown journal, 2024.